Literature DB >> 3493324

Purified influenza virus nucleoprotein protects mice from lethal infection.

D C Wraith, A E Vessey, B A Askonas.   

Abstract

Local administration of nucleoprotein purified from X31 (H3N2) influenza A virus primed for A virus cross-reactive cytotoxic T cells and resulted in substantial protection (75%) of mice from a lethal challenge with the heterologous mouse-adapted A/PR/8/34 (H1N1) virus. By following the course of a lethal virus challenge we found that nucleoprotein priming did not prevent virus infection but rather aided recovery. Nucleoprotein-primed mice suffered initial symptoms of infection, i.e. weight loss and surface temperature changes, but started to recover after approximately 7 days. We suggest that such heterotypic protection can be attributed to priming of A virus cross-reactive cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493324     DOI: 10.1099/0022-1317-68-2-433

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  48 in total

1.  Immunogenic properties of ISCOM prepared with influenza virus nucleoprotein.

Authors:  H P Weiss; L Stitz; H Becht
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Bacterially expressed nucleoprotein of infectious hematopoietic necrosis virus augments protective immunity induced by the glycoprotein vaccine in fish.

Authors:  L A Oberg; J Wirkkula; D Mourich; J C Leong
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice.

Authors:  H H Nguyen; F W van Ginkel; H L Vu; M J Novak; J R McGhee; J Mestecky
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 4.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

5.  Influenza virus-infected epithelial cells present viral antigens to antigen-specific CD8+ cytotoxic T lymphocytes.

Authors:  H H Nguyen; P N Boyaka; Z Moldoveanu; M J Novak; H Kiyono; J R McGhee; J Mestecky
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses.

Authors:  M G Lee; K H Kim; K Y Park; J S Kim
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.

Authors:  B Dietzschold; H H Wang; C E Rupprecht; E Celis; M Tollis; H Ertl; E Heber-Katz; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

8.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Authors:  Damian M Carragher; Denise A Kaminski; Amy Moquin; Louise Hartson; Troy D Randall
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

10.  Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes.

Authors:  K Scheepers; H Becht
Journal:  Med Microbiol Immunol       Date:  1994-11       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.